Abivax SA
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
If you'd bought from year…
Same habit, different start year. Each row shows what a constant habit's worth of ABVX-PA would be worth today, had you started buying at that point in the asset's history.
| Started | $6/day$6/day coffee | $42/wk$42/week coffee |
|---|---|---|
| Year 1 (2015) — listing | $169,915 10.1× | $242,458 10.1× |
| Year 6 (2020) | $80,586 8.2× | $115,242 8.2× |
| Year 11 (2025) | $17,172 8.0× | $24,774 8.1× |
Repeated investment, no fees, dividends reinvested. $6/day coffee = $180 / month equivalent.
Popular scenarios with ABVX
For illustration only — not investment advice. Past performance is not indicative of future results.